This invention comprises pharmaceutical compositions for administering a biologically active compound to an animal. Particularly provided are proliposomal compositions that are advantageously used to deliver biologically active compounds to the gastrointestinal tract after oral administration.
대표청구항▼
What is claimed is: 1. A pharmacological composition for oral administration comprising a proliposomal preparation of a biologically active compound that is selected from the group consisting of a nutrient, hormone, nucleic acid, antibiotic drug, enzyme, antigen, antiviral drug, antineoplastic, ant
What is claimed is: 1. A pharmacological composition for oral administration comprising a proliposomal preparation of a biologically active compound that is selected from the group consisting of a nutrient, hormone, nucleic acid, antibiotic drug, enzyme, antigen, antiviral drug, antineoplastic, antiproliferative, peptide, glyburide, aspirin, and a protein, in a capsule or tablet, an enteric coating, and a protective coating, wherein the protective coating is underneath the enteric coating and in between the proliposomal preparation and the enteric coating, wherein the proliposomal preparation consists of a phospholipid, cholesterol, said biologically active compound, stearylamine, and an optional particle lubricant, where the weight amount of stearylamine is less than the weight amount of cholesterol, and where the weight amount of cholesterol is less than the weight amount of phospholipid. 2. A pharmacological composition according to claim 1 wherein the enteric coating is cellulose acetate phthalate or a poly(acrylate, methacrylate) copolymer. 3. A pharmacological composition according to claim 1 wherein the protective coating is hydroxypropyl methylcellulose, polyethylene glycol or ethylcellulose. 4. A pharmacological composition according to claim 1 wherein the protective coating further comprises a plasticizer that is triethylcitrate or polyvinyl pyrrolidine. 5. A pharmacological composition according to claim 1, wherein the prolipsomal preparation consists of a phospholipid, cholesterol, said biologically active compound, and a particle lubricant that is talc, lactose, corn starch, ethyl cellulose, fatty acids or salts thereof, agar, pectin, gelatin or acacia. 6. A pharmacological composition according to claim 1 wherein the phospholipid is a phosphatidylcholine, or a phosphatidylethanolamine. 7. A pharmacological composition according to claim 6 wherein the phosphatidylcholine is distearylphosphatidylcholine, dimyristylphosphatidylcholine or a mixture thereof. 8. A pharmacological composition according to claim 7 wherein the phosphatidylcholine is distearylphosphatidylcholine. 9. A pharmacological composition according to claim 7 wherein the phosphatidylcholine is dimyristylphosphatidylcholine. 10. A pharmacological composition according to claim 1, wherein the biologically active component is glyburide, dideoxyinosine, or aspirin. 11. A pharmacological composition according to claim 1, wherein the biologically active component is glyburide, dideoxyinosine, or aspirin; and the phosphoplipid is a phosphatidylcholine, which is distearylphosphatidylcholine, dimyristylphosphatidylcholine or a mixture thereof. 12. A method for increasing the bioavailability of a biologically active compound that is selected from the group consisting of a nutrient, hormone, nucleic acid, antibiotic drug, enzyme, antigen, antiviral drug, antineoplastic, antiproliferative, peptide, glyburide, aspirin, and a protein, said method comprising orally administering to an animal in need thereof a proliposomal preparation of said biologically active compound in a capsule or tablet comprising an enteric coating, and a protective coating wherein the protective coating is underneath the enteric coating and wherein the proliposomal preparation consists of a phospholipid, cholesterol, said biologically active compound, stearylamine, and an optional particle lubricant, where the weight amount of stearylamine is less than the weight amount of cholesterol, and where the weight amount of cholesterol is less than the weight amount of phospholipid. 13. A method according to claim 12 wherein the animal is a human. 14. A method according to claim 12 wherein the enteric coating is cellulose acetate phthalate or a poly (acrylate, methacrylate) copolymer. 15. A method according to claim 12 wherein the protective coating is hydroxypropyl methylcellulose, polyethylene glycol or ethylcellulose. 16. A method according to claim 12 wherein the phospholipid is a phosphatidylcholine. 17. A method according to claim 12 wherein the protective coating further comprises a plasticizer that is triethylcitrate or polyvinyl pyrrolidine. 18. A method according to claim 12 wherein the biologically active compound is glyburide. 19. A method according to claim 12 wherein the phospholipid is a phosphatidylcholine, or a phosphatidylethanolamine. 20. A method according to claim 19 wherein the phospholipid is a phosphatidylcholine, which is distearylphosphatidylcholine, dimyristylphosphatidylcholine or a mixture thereof. 21. A method according to claim 20 wherein the phosphatidylcholine is distearylphosphatidylcholine. 22. A method according to claim 20 wherein the phosphatidylcholine is dimyristylphosphatidylcholine. 23. A method according to claim 12, wherein the biologically active component is glyburide, dideoxyinosine, or aspirin; and the phospholipid is a phosphatidylcholine, which is distearylphosphatidylcholine, dimyristyiphosphatidyicholine or a mixture thereof. 24. A method for delivering a biologically active compound to the intestine or colon, said method comprising orally administering to an animal in need thereof a proliposomal preparation of a biologically active compound that is selected from the group consisting of a nutrient, hormone, nucleic acid, antibiotic drug, enzyme, antigen, antiviral drug, antineoplastic, antiproliferative, peptide, glyburide, or aspirin and a protein, in a tablet comprising an enteric coating, and a protective coating wherein the protective coating is underneath the enteric coating and wherein the proliposomal preparation consists of a phospholipid, cholesterol, said biologically active compound, stearylamine, and an optional particle lubricant, where the weight amount of stearylamine is less than the weight amount of cholesterol, and where the weight amount of cholesterol is less than the weight amount of phospholipid. 25. A method according to claim 24 wherein the protective coating is hydroxypropyl methylcellulose, polyethylene glycol or ethylcellulose. 26. A method according to claim 24 wherein the phospholipid is a phosphatidylcholine. 27. A method according to claim 24 wherein the protective coating further comprises a plasticizer. 28. A method according to claim 24 wherein the plasticizer is triethylcitrate or polyvinyl pyrrolidine. 29. A method according to claim 24 wherein the proliposomal preparation consists of a phospholipid, cholesterol, said biologically active compound, stearylamine, and a particle lubricant that is talc, lactose, corn starch, ethyl cellulose, fatty acids or salts thereof, agar, pectin, gelatin or acacia. 30. A method according to claim 24 wherein the phospholipid is a phosphatidylcholine, or a phosphatidylethanolamine. 31. A method according to claim 30, wherein the phosphatidylcholine is distearylphosphatidylcholine, dimyristylphosphatidylcholine or a mixture thereof. 32. A pharmacological composition according to claim 31 wherein the phosphatidylcholine is dimyristylphosphatidylcholine. 33. A method according to claim 31 wherein the phosphatidylcholine is distearylphosphatidylcholine. 34. A method according to claim 24, wherein the biologically active component is glyburide, dideoxyinosine, or aspirin; and the phosphatidylcholine is distearyiphosphatidylcholine, dimyristyiphosphatidylcholine or a mixture thereof. 35. A method of treating diseases that cause or result in malabsorption in a human or animal, said method comprising administering a proliposomal preparation of a biologically active compound that is selected from the group consisting of a nutrient, hormone, nucleic acid, antibiotic drug, enzyme, antigen, antiviral drug, antineoplastic, antiproliferative, peptide, a protein, glyburide, and aspirin, in a capsule or tablet comprising an enteric coating, and a protective coating, wherein the protective coating is underneath the enteric coating and in between the proliposomal preparation and the enteric coating, wherein the proliposomal preparation consists of a phospholipid, cholesterol, said biologically active compound, and stearylamine, and an optional particle lubricant, where the weight amount of stearylamine is less than the weight amount of cholesterol, and where the weight amount of cholesterol is less than the weight amount of phospholipid, to a domesticated animal or a human in need thereof. 36. A method according to claim 35 wherein the enteric coating is cellulose acetate phthalate or a poly (acrylate, methacrylate) copolymer. 37. A method according to claim 35 wherein the protective coating is hydroxypropyl methylcellulose, polyethylene glycol or ethylcellulose. 38. A method according to claim 35 wherein the protective coating further comprises a plasticizer that is triethylcitrate or polyvinyl pyrrolidine. 39. A method according to claim 35, wherein the proliposomal composition consists of a phospholipid, cholesterol, said biologically active compound, stearylamine, and a particle lubricant that is talc, lactose, corn starch, ethyl cellulose, fatty acids or salts thereof, agar, pectin, gelatin or acacia. 40. A method according to claim 35 wherein the phospholipid is a phosphatidylcholine, or a phosphatidylethanolamine. 41. A method according to claim 40 wherein the phosphatidylcholine is distearylphosphatidylcholine, dimyristylphosphatidylcholine or a mixture thereof. 42. A method according to claim 41 wherein the phosphatidylcholine is distearylphosphatidylcholine. 43. A method according to claim 41 wherein the phosphatidylcholine is dimyristylphosphatidylcholine. 44. A method according to claim 35, wherein the biologically active component is selected from the group consisting of ibuprofen, erythromycin, vasopressin, insulin, dideoxyinosine, cyclosporin, taxol, heparin, halofantrine, ethopropazine, griseofulvin, propofol, furosemide, carbamazepine, diazepam, candesartan, cilexetil, glyburide, dideoxyinosine, and aspirin. 45. A method according to claim 44, wherein the biologically active component is glyburide, dideoxyinosine, or aspirin; and the phospholipid is phosphatidylcholine, which is distearylphosphatidylcholine, dimyristylphosphatidylcholine or a mixture thereof. 46. A method according to claim 35, wherein the disease is Crohn's disease, irritable bowel syndrome, celia sprue, diverticulitis, immunoproliferative small intestine disease, liver disease, diseases and disorders of the gall bladder, disorders that are consequent to the removal of the gall bladder, pancreatitis, Schwachman's syndrome, steatorrhea, Whipple's disease, parasitic infection, malabsorption as a consequence of chronic laxative use or abuse, pancreatic enzyme deficiency, disaccharidase deficiency, or defects in fat absorption consequent to surgical gastrectomy or other surgical interventions in the gastrointestinal tract.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (40)
Leigh Steven (Croydon GB2), Composition and method.
Brown Dell G. (Provo UT) Ward Marc K. (Provo UT) Dees H. Craig (Knoxville TN), Composition containing liposome-entrapped grapefruit seed extract and method for making.
John Phillip M. (East Greenbush NY) Belanger Raymond J. (Rensselaer NY) Paikoff Myron (Colonie NY), Easily-swallowed, powder-free and gastric-disintegrable aspirin tablet thinly-coated with hydroxypropyl methylcellulose.
Banholzer Rolf,DEX ; Bauer Rudolf,DEX ; Reichl Richard,DEX, Esters of bi- and tricyclic amino alcohols, their preparation and their use in pharmaceutical compositions.
Banholzer Rolf (Ingelheim am Rhein DEX) Bauer Rudolf (Ockenheim DEX) Reichl Richard (Gau-Algesheim DEX), Esters of bi-and tricyclic amino alcohols and their use in pharmaceutical compositions.
Banholzer Rolf (Ingelheim am Rheim DEX) Bauer Rudolf (Wiesbaden DEX) Reichl Richard (Ingelheim am Rheim DEX), Esters of thienyl carboxylic acids and amino alcohols and their quaternization products.
Bally Marcel B. (Bowen Island CAX) Boman Nancy L. (Richmond CAX) Cullis Pieter R. (Vancouver CAX) Mayer Lawrence D. (North Vancouver CAX), Liposomal compositions for enhanced retention of bioactive agents.
Lerner E. Itzhak,ILX ; Flashner Moshe,ILX ; Penhasi Adel,ILX, Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps.
Payne Nicholas I. (Merseyside GBX) Timmins Peter (Merseyside GBX) Ambrose Cheryl V. (London GBX), Method of preparing liposomes and products produced thereby.
Lichtenberger Lenard ; Butler Bruce D, Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein.
Hostetler Karl Y. (Del Mar CA) Sridhar Nagarajan C. (Simi Valley CA), Prodrugs for oral administration containing taxol or substituted taxol covalently bound to a phospholipid.
Calvo Salve Pilar,ESX ; Alonso Fernandez Maria Jose,ESX ; Remunan Lopez Carmen,ESX ; Vila Jato Jose Luis,ESX, Stabilization of colloidal systems through the formation of lipid-polyssacharide complexes.
Wheatley Margaret A. (Arlington MA) Langer Robert S. (Somerville MA) Eisen Herman N. (Waban MA), System for delayed and pulsed release of biologically active substances.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.